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Summary
Minor histocompatibility (mH) antigens appear to play a major role in bone marrow transplantation
(BMT) usingHLAidentical donors. Previously, we reported the isolation of major histocompati-
bility complex (MHC)-restricted mH antigen-specific cytotoxic T lymphocytes (CTL) from patients
with graft-vs.-host disease or rejection after HLA-identical BMT We have demonstrated that
mH antigens can be recognized on hematopoietic progenitor cells, and residual recipient CTL
specific for mH antigens expressed on donor hematopoietic progenitor cells may be responsible
for graft rejection in spite of intensive conditioning regimens in HLA-identical BMT. Here, we
investigated whether mH antigen-specific CTL directed against the mH antigens HA-1 to HA-5
and the male-specific antigen H-Y were capable of antigen-specific inhibition of in vitro growth
of clonogenic leukemic precursor cells. We demonstrate that mH antigen-specific CTL against
all mH antigens tested can lyse freshly obtained myeloid leukemic cells, that these mH antigen-
specific CTL can inhibit their clonogenic leukemic growth in vitro, and that this recognition
is MHC restricted. We illustrate that leukemic (precursor) cells can escape elimination by mH
antigen-specific CTL by impaired expression of the relevant MHC restriction molecule. We suggest
that mH antigen-specific MHC-restricted CTL may be involved in vivo in the graft-vs.-leukemia
reactivity after BMT
A
er
￿
tallogeneic bone marrow transplantation (BMT)t for
malignant hematologic diseases, relapse of the disease
is one of the major complications. Since T lymphocytes have
been removed from the bone marrow graft to prevent the
occurrence of acute graft-vs.-host disease (GGVHD), an in-
creased incidence of relapse of the leukemia has been found
(1). Furthermore, in HLA-identical BMT, an inverse correla-
tion has been found between the occurrence ofGVHD medi-
ated by donor-derived T lymphocytes and a relapse ofleukemia
(1). These observations have led to the hypothesis that donor-
derived T lymphocytes may be responsible for the graft-vs.-
leukemia (GVL) reactivityin allogeneic BMT. Since this GVL
reactivity has not been observed in transplants between
1 Abbreviations used in this paper. GGVHD, acute graft-vs.-host disease;
AML, acute myeloid leukemia; BMT, bone marrow transplantation; CML,
chronic myeloid leukemia; GVL, graft-vs.-leukemia; HPC, hematopoietic
progenitor cells; mH, minor histocompatibility.
homozygous twins, it has been suggested that alloantigen-
specific CTL may be responsible for the GVL reactivity after
transplantation. In BMT between HLA-identical sibling
donors, donor-derived alloreactive lymphocytes directed against
recipient antigens can not be directed against MHC antigens,
and are therefore by definition directed against minor histocom-
patibility (mH) antigens (2, 3).
mH antigens appear to play a major role in BMT using
HLA-identical donors (2, 3). Previously, we reported the iso-
lation ofMHC-restricted mH antigen-specific CTL from pa-
tients with GVHD or rejection after HLA-identical BMT
(2, 4-6). We have demonstrated that mH antigens can be
recognized on hematopoietic progenitor cells (HPC) (7-9),
and that residual recipient CTL specific for mH antigen ex-
pressed on donor HPC may be responsible for graft rejection
in spite of intensive conditioning regiments in HLA-identical
BMT (6). Furthermore, mH antigen disparity between donor
and recipient has been associated with the occurrence of
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appears to be a strong anti-mH antigen reactivityagainst the
recipient mH antigens, probably associated with a low inci-
dence of relapse after transplantation (1-3, 10, 11) .
To study whether the GVL reactivity may be caused by
donor-derived CTL specific for mH antigen expressed on re-
cipient tissues, we investigated whether mH antigen-specific
CTL were capable of antigen-specific inhibition of in vitro
growth of clonogenic leukemic precursor cells. We demon-
strate that mH antigen-specific CTL can lyre freshly obtained
myeloid leukemic cells, and can inhibit the in vitro growth
ofclonogenicleukemic precursor cells. We therefore suggest
that mH antigen-specific MHC-restricted CTL may be in-
volved in the in vivo GVL reactivity after BMT
Materials and Methods
Leukemic Samples.
￿
Samples of leukemic cells from patients
suffering from acute myeloid leukemia (AML) or chronic myeloid
leukemia (CML) were obtained, after informed consent, from the
peripheralblood or bone marrow of the patients before treatment.
Patients who had >95% morphologically recognizable leukemic
cells in theirperipheralblood or bone marrow samples were selected.
The cells were centrifuged over :Ficoll Isopaque (density 1.077/
cm', 1,000 g, 20 min) and the interphasecells were harvested. The
cells were cryopreserved in liquid nitrogen as described previously
(12). Leukemic samples were selected that gave rise to >100 leu-
kemic colonies per 104 cells plated in semisolid medium cultures.
Before use, the cells were thawed, washed twice, and resuspended
in IMDM containing 15% prescreened human AB serum.
Lymphocyte Populations. The lymphocyte populations were
generated by stimulating peripheral blood cells from the patient
with PHA (0.8 kg/ml for 3 d), followed by culturing at least 3 d
in the absence of PHA in the presence of human rIIL2 (50 U/ml)
(9). Using FACS® (Becton Dickinson & Co., Mountain View,
CA), the lymphocytesuspensions where shown to contain >90%
CD3' cells.
Generation of mH Antigen-specific CTL Clones.
￿
mH antigen-
specific CTL lines were generatedby stimulating donor-originated
peripheral blood cells obtained from recipients after HLA geno-
typically identical BMT with irradiated peripheral blood cells
obtained from the recipients before transplantation, as described
previously(2-5). The mH antigen-specific CTL lines were subse-
quently cloned by limiting dilution in the presence of recipient-
derived EBVtransformed lymphoblastoid cell lines (EBV lines) and
third party peripheral blood feeder cells in the presence of IL2.
CTL clones were obtained with specific cytotoxic activity for each
of the mH antigen specificities described previously(2), i.e., HA1,
HA-2, HA-3, HA-4, or HA-5 (Van Els, C.A.C.M., J. D'Amaro,
E. BIokland, A. Bakker, P.J. Van den Elsen, JJ. van Rood, and
E. Goulmy, manuscript submitted for publication). The MHC class
I-restricted mH antigen specificity of these CD8' CTL clones
was demonstrated by differential recognition oflymphocytes from
various HLA genotypically identical sibling pairs, and population
studies (2). In a random population, the frequency of the mH an-
tigens on the lymphocytes from individuals expressing the relevant
class I restricting molecule was 68% for HA-1, 96% for HA-2,
87% for HA-3,16%a for HA-4,and 8% for HA-5 (datanot shown).
In some experiments, an HLAA2-restricted HYspecific CTL clone
was used, generated from a female patient rejecting the HLA-
identicalbone marrow graftfrom a male donor(4). HA1-, HA2-,
HA4-, and HA-5-specific recognition was shown to be restricted
by HLAA2. HA-3 recognition was restricted by HLAA1 (2).
51Cr Release Assay. Standard "Cr release assays were performed
as described (13). Briefly, target cells consistingoflymphocyte popu-
lations or leukemic cells were labeled with 0.1 ml Nat 5'Cr04 (100
,uCi)for 1 h at 37°C, washed threetimes, and resuspended in RPMI
plus 15% serum at a concentration of 5 x 104 viable cells/ml. 0.1
ml of the effector cell population and 0.1 ml of the target cell sus-
pension were added to each well of a round-bottomed microtiter
plate at E/T ratios ranging from 10:1 to 0.1:1. To measure sponta-
neous release of 5'Cr, 0.1 ml of the target cell suspension was
added to 0.1 ml RPMI plus 15% serum without effector cells. Max-
imum release was determined by adding 0.1 ml of the target cell
suspensionto 0.1 ml ofZaponine solution. The percentageof specific
lysis was determined as follows: 10ox (experimental release cpm
- spontaneous release cpm)/(maximum release cpm - sponta-
neous release cpm).
Cell-mediated Inhibition of Clonogenic Leukemic Precursor Cell
Growth. 104 leukemic cells in 0.1 ml medium consisting of
IMDM plus 15% human AB serumwas mixedwith CTL at E/T
ratios varying from 10:1 to 0.1:1. The cell mixture was centrifuged
(1,000 g, 15 s) to establish cell-cell contact between CTL and leu-
kemiccells, and then incubated for 4 h at 37°C. After incubation,
the cells were resuspended and cultured as a single cell suspension
at a concentration of 104 leukemic cells/ml in 30-mm culture
dishes in 1 ml IMDM containing 20% prescreened human AB
serum, 20% PHA-stimulated leukocyte-conditioned medium (PHA-
LCM), 100 U/ml recombinant human granulocyte/macrophage
CSF, human transferrin, 5 x 10-5 M mercaptoethanol, and
methylcellulose at a final concentration of 1.1%. The cells were
incubated in the fully humidified atmosphere of 5% C02 and
37°C, and leukemic colonies, consisting of at least 20 cells, were
counted after 10--14 d ofculture. Morphological and/or cytogenetic
analyses of several representative leukemic colonies isolated from
the cultures were performed. Inhibition of leukemic growth was
expressed as the percentage decrease of the number of colonies as
compared with control cultures, grown in the absence of effector
cells. To control for antigen-nonspecific inhibition ofcolony growth
due to the secretion ofhumoral inhibitoryfactors into the culture
medium, effector cells were also plated together with the leukemic
cells at the same E/T ratios directly in the semisolid medium,
without preincubation, to prevent cell-cell contact.
Results
The PHA-stimulated lymphocytes from patients with
leukemia of various subtypes according to the FAB clas-
sification were HLA typed. Since the mH antigen-specific
CTL clones were shown to be HLAA1 or HLAA2restricted,
only patients expressing HLAAl and/or -A-2 on their lym-
phocytes were selected for the study. Table 1 shows the char-
acteristics of the patients and the leukemic samples used. Rep-
resentative leukemic colonies were isolated from the cultures,
and morphological and/or cytogenetic analysis of these colo-
nies revealed that the cells recovered had characteristics iden-
tical to the original leukemic population. In one of the two
cases with CML, the progeny harvested from the colonies
showed additional cytogenetic abnormalities (data not shown).
Furthermore, the high percentage of the leukemic cells in
the samples used, in combination with the high plating
efficiency, excluded the possibility of a significant contribu-
28
￿
Minor Histocompatibility Antigens on Clonogenic Leukemic Precursor Cellstion ofcolonies derived from residual normal progenitor cells
present in the cell suspension (Table 1).
A good correlation was found between the antigen-specific
lysis of the lymphocytes and the leukemic cells in a 5'Cr re-
lease assay, and the inhibition of the clonogenic leukemic
precursor cell growth by the mH antigen-specific CTL clones.
Fig. 1 shows a representative experiment with the cells of
a patient with AML. CTL clones directed against HA-3 or
HLA-A1 that gave dose-dependent lysis of the lymphocytes
of the patient showed similar cytotoxicity against the AML
blasts (Fig. 1, A and B). When cell-cell contact between the
CTL clones and the leukemic cell populationwas established
for 4 h before plating the cells as a single cell suspension in
the semisolid culture medium, strong dose-dependent, antigen-
specific inhibition of the clonogenic leukemic growth was
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observed (Fig. 1 C). When the effector/target cells were plated
directly together as a single cell suspension in the semisolid
medium, thereby prohibiting direct cell-cell contact between
effector cells and target cells, no growth inhibition was ob-
served. This illustrated that cell-cell contact was necessary
for the observed growth inhibition (Fig. 1 D) (7, 8).
Results of experiments with cells of three representative
patients with AML of different subtypes, and of one of the
two patients with CML, are shown in Fig. 2. The left panels
show the result of lysis of lymphocytes or leukemic cells by
the mH antigen-specific CTL clones or anti-HLA class I CTL
clones in a 4-h "Cr release assay. The data are expressed as
means ± SD of the highest E/T ratios used (10:1 or 5:1)
in three to nine experiments performed in duplicate. The right
panels illustrate the inhibition of the clonogenic leukemic
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Figure 1.
￿
Cell-mediated lysis oflymphocytes
or leukemic cells, and cell-mediated inhibition
ofleukemic colony growth byCTL clones. Lysis
of lymphocytes or leukemic blast cells by the
CTL clones was measured using a standard
"Cr release assay in duplicate at E/T ratio's
varying from 10:1 to 0.1:1 (leftpanels).Growth
inhibition by the CTL clones was measured by
preincubating the leukemic cells before plating
with irradiated effector cells at E/T ratio's
varying from 10:1 to 0.1:1 (C). As a control,
effector cells and leukemic cells at the same E/T
ratios were plated directly in the semisolid
medium, without preincubation, to prevent
cell-cell contact (D).
Table 1 . Characteristics of the
Patient HLA type
Leukemic Cells
FAB classification Karyotype No. of colonies per 104 cells
1 A2, B27,44 AML M1 46XX 243
2 A1,9 B8,w41 AML M2 46XX 189
3 A1,2 B49,w56 AML M4 46XX,-7, + t(1;7)(g11 ;p11) 577
4 A1,3 Bw57,35 AML M5 46XX 310
5 A2,3 B7,27 AML M2 47XY, + 13 249
6 A2,26 B7,44 AML M1/2 46XX 624
7 A2, B8,40 AML M5 46XX 259
8 A2, B7,27 CML CP* 46XX, t(9;22) 326
9 A1,2 B8,13 CML CP* 46XY, t(9;22) 182
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colony growth after a 4-h preincubation of the leukemic
cells with the CTL clones. 104 leukemic cells were incubated
with 105, 104, or 103 irradiated (20 Gy) CTL in lMDM
with 15% serum. Then, the cells were resuspended and plated
as single cell suspensions in semisolid medium cultures as de-
scribed in Materials and Methods. Percentage growth inhibi-
tion was expressed as percentage decrease in the number of
colonies counted after 14 d as compared with control leu-
Leukemic growth inhibition
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Figure 2.
￿
mH antigen-specific lysis of lym-
phocytes or leukemic cells, and inhibition of
leukemic colony formation by mH antigen-
specific CTL clones. The left panels show the
results oflysis oflymphocytes or leukemic cells
by the mH antigen-specific CTL clones and/or
by HLA-A1 or -A2 CTL clones. The data are
expressed as mean ± SD of the highest E/T
ratios used (10:1 or 5:1) in three to nine ex-
periments performed in duplicate. The right
panels illustrate the inhibition of clonogenic
leukemic colony growth after 4 h of preincu-
bation of the leukemic cells with CTL clones
at E/T ratios varying from 10:1 to 0.1:1.
kemic colony growth in the absence of effector cells. As a
control for nonspecific inhibition ofleukemic growth by factors
secreted by the CTL clones, in all experiments leukemic cells
were also cultured in the presence of the same number of
effector cells in the semisolid culture medium without the
4-h preincubation in liquid medium. These cultures did not
show significant growth inhibition as compared with the con-
trol culture in the absence of effector cells (data not shown).
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0 0Effector cells plated in the absence of leukemic cells did not
form colonies (data not shown). It was demonstrated that
similar to the lysis in the s'Cr release assay, antigen-specific
dose-dependent inhibition of the clonogenic leukemic pre-
cursor cell growth wasobserved, even at very lowE/T ratios
(Fig. 2, right panels).
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Results show specific lysis of target cells or inhibition of clonogenic leukemia growth.
Mean lysis or inhibition of three to nine experiments is presented.
-: 0-20% lysis or inhibition; (+): 20-30% lysis or inhibition; + : 30-50% lysis or inhibition;
' Percentage specific lysis of lymphocytes or leukemic cells in s1Cr release assay.
s Percentage inhibition in clonogenic leukemic precursor cell assay.
+ + : >50% lysis or inhibition.
The results of the experiments with all nine patients are
summarized in Table 2. A strong correlation between the
antigen-specific lysis of the lymphocytes, thelysis of the leu-
kemic cells, and the inhibition of the clonogenic leukemic
precursorcell growth was observed forallmH antigen-specific
CTL clones tested. In addition, the HLAA2-restricted anti-
Table 2. Reactivity of
Precursor Cells
mH-specific Cytotoxic T Cell Clones with Normal Lymphoblasts, Leukemic Cells, and Clonogenic Leukemic
Patients
CTL clone 1 2 3 4 5 6 7 S 9
HA-1:
Lympholysis* - - + + - -
Leukemic lysis' - - + + - -
Growth inhibitions - - + + - -
HA-2:
Lympholysis* + + - + + - - (+) +
Leukemic lysis' + - + + - - (+) (+)
Growth inhibitions + - + + - -
HA-3:
Lympholysis* - + + + + + + -
Leukemic lysis" - + + + + + + -
Growth inhibitions - + + + + + + -
HA-4:
Lympholysis* - - - - -
Leukemic lysis* - - - - -
Growth inhibitions - - - (+) -
HA-5:
Lympholysis* + - - - (+)
Leukemic lysis' + - - - (+)
Growth inhibitions + + - - - +
Anti-Al:
Lympholysis* - + + + + + + -
Leukemic lysis' - + + + + + + -
Growth inhibitions - + + + + + + -
Anti-A2:
Lympholysis* + + - + + ' - + +
Leukemic lysis* + + - + + - + +
Growth inhibitions + + - + + - + +
Anti-H-Y :
Lympholysis* + +
Leukemic lysis' +
Growth inhibitions + +H-Y CTL clone showed strong reactivity with both lym-
phocytes and leukemic cells from HLA-A2-positive male pa-
tients. As expected, no lymphocytes or leukemic cells from
patients negative for HLAA1 and -A2 showed reactivitywith
the CTL clones (data not shown). Only lymphocytes or leu-
kemic cellsfrom HLA-Al-positive patients showed reactivity
with the anti-HA-3 CTL clone, and only lymphocytes or
leukemic cells from HLAA2-positive patients showed reac-
tivity with the anti-HA-1, -HA-2, -HA-4, -HA-5, and -HLA
A2-restricted HY CTL clones, illustrating that similar to
the lymphocytes, the recognition ofthe leukemic cells is HLA
class I restricted (Table 2) .
In one case, patient 6, the AML cells showed no reactivity
with the anti-HA-2 CTL clone, although the lymphocytes
were clearly lysed (Table 2). Furthermore, the control anti-
HLA-A2 clone did not react with the leukemic (precursor)
cells. Serological typing of the leukemic cells revealed that
the leukemic cell populationdid not express the class I HLA-
A2/B44 antigens, whereas the other haplotype (HLAA26/B7)
was normally expressed, as well as both class II haplotypes.
Therefore, impaired recognition of this leukemic cell popu-
lation by the anti-HA-2 CTL clone appeared to be due to
the loss of expression ofthe relevant classI restriction molecule.
Discussion
Our results show that leukemic (precursor) cells express
mH antigens. CTL clones directed against these mH antigens
are not only capable oflysis of freshly obtained leukemic cells,
but are capable ofantigen-specific growth inhibition ofclono-
genic leukemic precursor cells, illustrating that the leukemic
precursor cells are susceptible targets for alloreactive MHC-
restricted mH antigen-specific T lymphocytes.
Recently, we showed that anti-host mH antigen-specific
reactivity can be found after HLA-identical BMT not only
in patients with GVHD, but also in patients without clinical
signs of GVHD, or after resolution of acute GVHD (14).
Consequently, the existence of anti-recipient mH CTL in
vivo does not always imply destruction of the GVHD target
organs. This is compatible with the differential expression
of mH antigens on keratinocytes (15 ; De Bueger, M.M.,
A. Bakker, J.J. van Rood, and E. Goulmy, manuscript sub-
mitted for publication). Previously, we illustrated that mH
antigens may be differentially recognized on normal hema-
topoietic progenitor cells (8). We have shown that the mH
antigens HY and HA-3 are expressed on peripheral blood
monocytes and lymphocytes, as well as hematopoietic pro-
genitor cells (7-8). In contrast, CTL lines specific for the
mH antigens HA-1, HA-2, HA-4, and HA-5 could lyse lym-
phocytes, but did not recognize hematopoietic progenitor cells
from the same individuals, indicating differential expression
of mH antigens on hematopoietic cells (8). These results in-
dicate that the expression of several mH antigens appeared
to be tissue specific, and some ofthese antigens maybe differen-
tiation antigens (3, 7, 8).
We have demonstrated that residual recipient CTL specific
for mH antigens expressed on donor hematopoietic progen-
itor cells may be responsible for graft rejection in spite of
intensive conditioning regiments after HLA-identical BMT
(6). These results illustrated that also in vivo, mH an-
tigen-specific CTL can be responsible for the elimination of
hematopoietic progenitor cells. Similarly, donor-derived mH
antigen-specific CTL may be capable of lysis of leukemic
precursor cells in vivo. Particularly in chronic GVHD, when
strong donor anti-recipient mH antigen reactivityis present
in the patient, a low incidence of relapse of the leukemia ap-
pears to occur (1-3, 10, 11). These results suggest that also
in vivo, mH antigen-specific CTL may be responsible for
a GVL effect. Since mH antigens may be differentially ex-
pressed on normal recipient tissue, and since the occurrence
of anti-recipient mH CTL in vivo (14) is not always cor-
related with GVHD, it may be hypothesized that certain mH
antigen reactivities after transplantation may cause a graft-
vs.-leukemia reactivity without concurrent GVHD.
In conclusion, in this report we demonstrate that mH an-
tigens can be recognized on fresh leukemic cells by MHC-
restrictedCTL. These mH antigen-specific CTL are capable
of growth inhibition of clonogenic leukemic precursor cells
in vitro, and may therefore be responsible for the GVL reac-
tivity that has been hypothesized in HLA-identical BMT Fur-
thermore, it may be conceivable that donor-derived CTL clones
that recognize the neoplastic target cells from the recipient
but not the normal host cells of the tissues that are involved
in GVHD may be used as an adjuvant immunotherapy in
a treatment of leukemia.
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